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AbstrACt
Introduction Randomised controlled trials (RCTs) are 
widely viewed to generate the most reliable medical 
knowledge. However, RCTs are not always scientifically 
necessary and therefore not always ethical. Unfortunately, 
it is not clear when an RCT is not necessary or how this 
should be established. This study seeks to systematically 
catalogue justifications offered throughout the medical 
and ethics literature for performing randomisation within 
clinical trials.
Methods and analysis We will systematically search 
electronic databases of the medical literature including 
MEDLINE, EMBASE, Cochrane Database of Systematic 
Reviews, Cochrane Clinical Trials Register, Web of Science 
Proceedings,  ClinicalTrials. gov; databases of philosophical 
literature including Philosopher’s Index, Phil Papers, 
JSTOR, Periodicals Archive Online, Project MUSE, National 
Reference Centre for Bioethics; the library catalogue at the 
University of Ottawa; bibliographies of retrieved papers; 
and the grey literature. We will also pursue suggestions 
from experts in the fields of medical ethics, philosophy 
and clinical trial methodology. Article screening, selection 
and data extraction will be performed by two independent 
reviewers based on prespecified inclusion/exclusion 
criteria. A third reviewer will be consulted to resolve any 
discrepancies. We will then extract the reasons given 
to justify randomisation using methodology established 
to extract data in a defensible, systematic manner. We 
will track the reasons given, their frequency of use and 
changes over time. Finally, using grounded theory, we will 
combine the reasons into broader themes. These themes 
will form the foundation of our subsequent analysis from 
qualitative and quantitative perspectives. This review 
will map existing arguments that clinicians, ethicists and 
philosophers use to ethically justify randomisation in 
clinical trials.
Ethics and dissemination No research ethics board 
approval is necessary because we are not examining 
patient-level data. This protocol complies with the reported 
guidance for conducting systematic scoping reviews. 
The findings of this paper will be disseminated via 
presentations and academic publication. In a subsequent 
phase of this research, we hope to engage with 
stakeholders and translate any recommendations derived 
from our findings into operational guidelines.
IntroduCtIon
In modern medicine, randomised controlled 
trials (RCTs) are considered to generate the 
highest form of medical knowledge.1 However, 
an RCT is not required to answer every clin-
ical question, nor is every RCT ethical. For 
example, an RCT that deprives patients of 
a standard, proven therapy could be both 
scientifically unnecessary and unethical. 
There are, of course, less obvious examples 
in many fields of study that have generated 
controversy, including the well-described case 
of extracorporeal membrane oxygenation 
for neonatal respiratory failure.2 The crux 
of the problem relates to the use of rando-
misation as an experimental technique, in 
which patients are allocated to one of several 
treatment strategies, which may have varying 
degrees of support and which may not all be 
in the best interest of the patient.
In order to be able to determine when an 
RCT is justified, researchers, regulators and 
funders should be able to refer to a set of 
criteria that render RCTs scientifically and 
ethically justifiable. However, it is not entirely 
strengths and limitations of this study
 ► This study will ask a novel research question with 
broad applicability for investigators, research eth-
ics boards, funding agencies and government 
regulators.
 ► We will apply a rigorous, quantitative approach to an 
ethics problem, which has resisted a standardisable 
solution.
 ► We intend to produce a scoping review which in its 
data analysis will draw on methods typically associ-
ated with qualitative systematic reviews.
 ► The diversity of data included in the relevant liter-
ature presents a potential challenge from the per-
spective of interrater reliability and consistency in 
analysis.
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clear what criteria are currently used or what the optimal 
criteria should be. Our study aims to systematically review 
the bioethical literature to determine what justifications 
are being offered for randomisation within specific RCTs 
or for RCTs in general. As such, this review incorporates 
studies from ethics (ie. issues of values), epistemology 
(ie. issues of knowledge) and clinical research.
Much of the literature on the epistemic-ethical review 
of RCTs has focused on the principle of ‘equipoise’,3 a 
term introduced by American legal scholar Charles Fried 
in 1974.4 Fried argued that the criterion justifying a ther-
apeutic trial was ‘equipoise’, meaning uncertainty on the 
part of the enrolling physician about which of the treat-
ments is superior. Though Fried’s definition has since 
been criticised as an inconsistent and non-evidence–
based standard, it remains in use, often under the name 
of the ‘uncertainty principle'.5,6
In 1987, McGill bioethicist Benjamin Freedman argued 
that the justification for RCTs should depend on the 
existence of ‘clinical equipoise’, which he defined as 
‘honest, professional disagreement’ within the medical 
community.7 For Freedman, individual clinicians would 
be expected to disagree about the optimal treatment of 
a patient with a particular disease, and this disagreement 
was the condition that justified conducting an RCT.
Freedman’s ‘clinical equipoise’ remains the modern 
standard by which most RCTs are ethically evaluated.8 
Equipoise likely remains popular because its central 
notion—that there should be uncertainty about which 
treatment is best for a therapeutic RCT to be ethically 
justifiable—is deeply appealing to clinicians. In situations 
where equipoise is said to exist, clinicians can honestly say 
that they do not know which treatment is best and there-
fore cannot feel that a patient is being given an inferior 
treatment within the context of the RCT.
However, equipoise has also been subject to signifi-
cant criticism from ethicists,9 trialists10 and clinicians.11,12 
Translating the concept of equipoise into real-world 
practice has always been a challenge. For example, how 
much disagreement is necessary to justify a trial? How is 
this disagreement to be measured? Whose opinion is rele-
vant to any given question? If disagreement exists, should 
the basis for that disagreement—for example, science, 
economics, politics, influence— matter? Moreover, is the 
mixture of opinion within a medical community an accu-
rate reflection of the state of scientific knowledge on a 
given topic?
We suspect that ‘clinical equipoise’ incompletely 
describes the conditions that justify RCTs. From medical 
history, we know that a lack of disagreement does not 
mean a question has been adequately answered.13 More-
over, the need for knowledge translation activities demon-
strates how the presence of disagreement does not mean 
that a clinical question remains unanswered.14 As RCT 
design becomes increasingly complex (eg, with cluster 
and pragmatic trials),15,16 our conception of RCT ethics 
also needs to become more sophisticated. Therefore, we 
believe it is necessary to capture all the reasons offered 
in the medical, dental and other literature indexed on 
major health databases for justifying randomisation and 
RCTs. If a uniform set of reasons can be extrapolated, 
then these reasons may form the basis for the develop-
ment of a standardisable, transparent set of criteria to be 
used by researchers, regulators and funders when evalu-
ating proposed RCTs.
objECtIvEs
This systematic scoping review explores the reasons 
given to ethically justify the performance of thera-
peutic randomised clinical trials, in which patients are 
randomised to receive one of several different treat-
ments.17,18 In this project, we are concerned with elab-
orating the conditions that are taken to render RCTs 
ethically justifiable,19 by which we mean describing the 
features of the state of knowledge surrounding a research 
question that make it suitable to conduct an RCT. We 
have chosen to do a scoping review instead of a systematic 
review for several reasons: (1) the complexity and hetero-
geneity of the sources; (2) the need for including hetero-
geneous concepts and arguments to make this review 
more sensitive and inclusive; (3) the need for mapping 
these concepts first to identify broad and narrow reasons 
for justification and subsequently to apply an inductive 
process to achieve a more sensible framework.
The central question of this research project is as 
follows:
1. What reasons are given to ethically justify the perfor-
mance of RCTs?
Secondary questions include:
2. How often is ‘equipoise’ offered as a reason, and what 
definition of equipoise is implied and/or given?
3. Are there differences in how clinicians, ethicists and 
philosophers justify RCTs?
4. How have the reasons offered changed over time?
MEthods And AnAlysIs
This protocol complies with the reported guidance for 
conducting systematic scoping reviews.20 We will perform 
this study between October 2017 and September 2019 
and will generally reflect three stages: article search and 
selection, data extraction and analysis (figure 1).
Our data extraction process has been adapted from 
a methodology developed by Strech and Sofaer for the 
systematic review of the bioethical literature.21 This 
method is intended to address a heterogeneous literature 
by focusing exclusively on the reasons given for particular 
decisions or stances. As defined in Strech’s methodology, 
a reason can generally be defined as an explanation given 
for the views that a position is or is not correct. 22 In our 
case, these positions relate to the decisions to perform 
or not perform an RCT. As outlined in the Strech meth-
odology, we will not be performing an analysis of the 
quality of the papers in which the reasons appear or of 
the strengths of the arguments. This decision is made in 
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an attempt to limit the impact of bias in the assessment 
process by restricting our analysis (as much as possible) 
to the original texts.
Our analytical methods are closely aligned with the 
techniques of a qualitative systematic review (QSR), which 
is a recognised method for integrating findings from 
qualitative studies.23 We chose to follow a QSR method 
because our question relates to arguments rather than 
to quantitative data, and our sample includes literature 
from the bioethics, philosophy and medical domains. 
The QSR approach was selected to achieve methodolog-
ical rigour and apply a technique that would be familiar 
to medical researchers. Like other systematic reviews, a 
QSR applies a standard methodology to ensure that all 
relevant scholarship is captured. The main analytical 
process is not a quantitative meta-analysis but rather an 
integrative process that identifies common themes and 
concepts. For example, our analysis will be based on a 
grounded theory approach, in which iterations of anal-
ysis and discussion lead to the determination of themes 
through consensus. Grounded theory refers to a general 
research method in which the analysis of data begins with 
an inductive process (ie, based on prior knowledge and 
experiences) that is then modified during the course 
of the study as determined by the research findings. In 
this way, the theory that emerges is grounded in the data 
collected.
We anticipate that the reasons we will identify may 
include concepts related to equipoise, personal uncer-
tainty, group uncertainty and medical necessity, among 
others. However, these concepts will not be defined at the 
data extraction stage as we anticipate there to be incon-
sistencies in how individual words or phrases are used. 
For example, ‘equipoise’ may be used in reference to 
various different versions of the concept. Additionally, 
defining these concepts at the data extraction phase may 
bias data extraction. We anticipate that a key component 
of the data synthesis stage will be the organic develop-
ment of an organisational hierarchy of reasons and subse-
quent themes generated through a grounded theory 
methodology.
Patient and public involvement
Patients were not explicitly consulted in the design of 
this study, as the process under investigation—namely, 
how RCTs are ethically justified—usually occurs before 
and without patient participation. In future phases of this 
research, we will seek to engage patients on questions of 
RCT ethics.
ElIgIbIlIty CrItErIA
study characteristics
This systematic scoping review will include observational 
studies, interventional trials, philosophical scholarship, 
narrative reviews, editorials, commentaries and systematic 
reviews pertaining to the reasons given to justify randomi-
sation in clinical trials.
setting and time frame
This review will only include papers produced in 1948 or 
later, as that was the date of the first modern RCT. The 
dates of papers selected for inclusion will be captured 
during data extraction to enable the assessment of trends 
in the justifications offered for RCTs.
report characteristics
Articles written in English or French will be included, 
reflecting the authors’ language facility. We will only 
include complete articles that have been published. 
Abstracts or articles in press will be excluded.
Information sources
We will search electronic databases, grey literature and 
consult bibliographies and authors of selected papers. 
We will search electronic databases of the medical litera-
ture including MEDLINE, EMBASE, Cochrane Database 
of Systematic Reviews, Cochrane Clinical Trials Register, 
Web of Science Proceedings,  ClinicalTrials. gov and data-
bases of philosophical literature including Philosopher’s 
Index, Phil Papers, JSTOR, Periodicals Archive Online, 
Project MUSE and the National Reference Centre for 
Bioethics. We will also search the library catalogue of the 
University of Ottawa and solicit suggestions from experts 
in the fields of medical ethics and other philosophy and 
clinical trial methodologies. A number of related search 
Figure 1 Workflow.
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terms such as ethics, epistemology, clinical trials, rando-
misation and equipoise were combined to generate the 
original set of search criteria. Please see online supple-
mentary appendix 1 for the full search terms.
We will identify seminal papers and then review our 
search results to ensure the search methodology is appro-
priately inclusive.
dAtA ItEMs
We will collect the following bibliographic information 
from included studies: the first author, title of the paper, 
the journal in which it was published, year of publica-
tion and the classification of the first author (defined as 
being either a physician, ethicist/philosopher, regulator 
or historian). We will also categorise the article type into 
five broad categories derived from the National Library of 
Medicine classification: type 1: case reports, observational 
studies or clinical trials; type 2: commentaries, editorials, 
personal narratives or reviews; type 3: historical articles; 
type 4: philosophical articles; and type 5: government 
publications. We will collect the in-text citation for reasons 
given as justifications for RCTs. Because there are nearly 
infinite ways for authors to state a reason, data extractors 
will be instructed to look for formulations that followed 
the pattern of ‘a RCT is justified if X’ or ‘If X does not 
apply, then an RCT is unethical’ and variations on those 
structures. Please see table 1 for the data extraction form.
As outlined in the methodology developed by Strech 
and Sofaer for a systematic review of an ethics literature, 
we will not be explicitly performing a risk of bias assess-
ment in the manner typical of quantitative systematic 
reviews. The reasons for this are four-fold. First, we will 
not include the clinical outcomes of any clinical studies 
(which would be vulnerable to traditional biases), but 
only the justifications offered for those studies. Second, 
argumentative and qualitative data do not lend them-
selves to the risk of bias assessment common in quan-
titative systematic reviews, in that an argument will 
always be intentionally and overtly biased by the posi-
tion of the author. Third, we chose not to interpret 
the risk of bias assessment as a broad judgement on 
the quality of the manuscript because we are including 
many different types of manuscripts whose evaluations 
would have to be type-specific, and once again this was 
not felt to be relevant to our question. Fourth, we were 
concerned that quality assessments would be very diffi-
cult to standardise between reviewers and hence would 
inject unnecessary bias and heterogeneity into our own 
analyses.
dAtA CollECtIon And AnAlysIs
Citations will be imported into the Covidence systematic 
review management software and screened for selection 
by two reviewers using titles and abstracts; this process 
will be documented in a flow diagram according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses criteria. Then, data will be extracted inde-
pendently by two reviewers (with no blinding to authors 
or journal) using a standardised form described above. 
We will test the data extraction form with 10 studies. 
The results of these extractions will be compared for 
homogeneity, and then new instructions will be given to 
increase interrater reliability. On attaining high levels 
of agreement, we will proceed to full data extraction. 
Should any disagreement arise, discrepancies will be 
resolved by discussion, with involvement of a third 
reviewer when necessary. For instances where agree-
ment cannot be reached, we will note the potential 
arguments of each party and include them in the final 
data capture.
dAtA synthEsIs
On completion of data extraction, principal researchers 
will meet to combine the extracted reasons using a 
grounded theory approach based on methods elabo-
rated in Heath and Cowley.24 Reasons will be grouped 
by themes. These themes will then be placed within the 
broader context of medical bioethics. Both narrative 
and quantitative reviews will be produced. Specifically, 
we will quantify the number of reasons given, the rela-
tive frequency of their use, the relationship between 
reasons and author or paper types and any obvious 
changes over time. Interpretation will be qualitative, in 
that we will gather references to themes. The identifica-
tion of themes will lead to reconsideration of the rele-
vant literature, further refinement of themes and the 
generation of conclusions. Additionally, we will assess 
both the quality of our own search strategy as well as 
the quality of the thematic analyses produced.25 When 
Table 1 Data extraction form
Article Number
Last Name of First Author
Title
Journal
Year
First Author Type:
1. MD
2. philosopher/ethicist
3. REB/regulator
4. historian
Article Type:
1. case report, observational study or 
clinical trial
2. commentary, editorial or personal 
narrative or review
3. historical manuscript
4. philosophical manuscript
5. government document
What reason is given to justify 
randomization in a clinical trial?
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coding themes, unresolvable disagreements will be 
noted and discussed.
Presentation of results
We intend to present a list of the justifications offered, 
analysed by frequency of use, use over time and associ-
ations with author type. We will organise these justifica-
tions into themes and will address variations on those 
themes. These data will then be used to draw conclu-
sions about the scope of the field of ethical justification 
for RCTs and will inform future work on developing 
ethical guidelines and translating them into standard-
isable practices.
EthICs And dIssEMInAtIon
We will seek to publish our results in leading medical 
journals (eg, BMJ) and in leading bioethics journals 
(eg, Bioethics) with a focus on open access publication. 
Moreover, we plan to present the results, as well as the 
methodology of this systematic scoping review:
 ► to the local medical community through vehicles such 
as Grand Rounds;
 ► to the local clinical trials community, for example, in 
a seminar with the Department of Epidemiology and 
Community Medicine;
 ► to the local bioethics and philosophy communities, 
for example, through the Ottawa Hospital bioethics 
and philosophy of medicine rounds;
 ► and to national and international research communi-
ties through presentations at major meetings.
We will engage with research ethics board (REB) 
leaders and national regulators to identify collabora-
tors willing to participate in a future, synthetic phase of 
this project with the aim of developing a revised ethics 
framework for clinical trial evaluation. We are also 
exploring the central question of this review through a 
series of interviews with trialists, philosophers and REB 
chairs. We hope to integrate this separate analytical 
method with the results of the systematic scoping review 
described here. Until the results of these two studies are 
known, further plans for knowledge translation would 
be premature.
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